X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1165) 1165
male (811) 811
glucosides - therapeutic use (659) 659
diabetes mellitus, type 2 - drug therapy (655) 655
female (604) 604
animals (571) 571
glucosides - pharmacology (499) 499
glucosides - adverse effects (471) 471
middle aged (464) 464
hypoglycemic agents - therapeutic use (426) 426
pharmacology & pharmacy (403) 403
type 2 diabetes (402) 402
diabetes (386) 386
benzhydryl compounds - therapeutic use (368) 368
glucose (365) 365
glucosides - administration & dosage (333) 333
sodium-glucose transporter 2 - antagonists & inhibitors (325) 325
adult (321) 321
endocrinology & metabolism (316) 316
aged (303) 303
hypoglycemic agents - adverse effects (303) 303
double-blind (300) 300
dapagliflozin (294) 294
treatment outcome (289) 289
benzhydryl compounds - adverse effects (271) 271
mice (242) 242
rats (229) 229
analysis (221) 221
diabetes mellitus (216) 216
diabetes mellitus, type 2 - blood (213) 213
metformin (213) 213
care and treatment (211) 211
double-blind method (210) 210
dextrose (204) 204
hypoglycemic agents - administration & dosage (199) 199
sglt2 inhibitor (196) 196
blood glucose - drug effects (194) 194
empagliflozin (188) 188
blood glucose - metabolism (186) 186
canagliflozin (177) 177
safety (177) 177
drug therapy, combination (173) 173
dose-response relationship, drug (172) 172
benzhydryl compounds - administration & dosage (168) 168
clinical trials (162) 162
insulin (160) 160
oxidative stress (155) 155
inadequate glycemic control (143) 143
risk factors (139) 139
hypoglycemic agents - pharmacology (138) 138
inflammation (135) 135
mellitus (134) 134
diabetes mellitus, type 2 - complications (133) 133
research (133) 133
sodium (133) 133
glucosides - pharmacokinetics (131) 131
drug therapy (130) 130
efficacy (130) 130
glycemic control (130) 130
biochemistry & molecular biology (129) 129
hyperglycemia (127) 127
internal medicine (126) 126
thiophenes - therapeutic use (121) 121
blood pressure (120) 120
glucosides (120) 120
body weight (115) 115
glucosides - chemistry (115) 115
rodents (115) 115
young adult (115) 115
body weight - drug effects (114) 114
glycated hemoglobin a - metabolism (114) 114
diabetes mellitus, type 2 - metabolism (112) 112
type 2 diabetes mellitus (112) 112
benzhydryl compounds - pharmacology (111) 111
health aspects (111) 111
diabetes therapy (110) 110
chemistry, medicinal (107) 107
mortality (106) 106
toxicology (104) 104
metabolism (103) 103
blood pressure - drug effects (100) 100
hypoglycemic agents (100) 100
add-on (98) 98
benzhydryl compounds (98) 98
food science & technology (96) 96
medicine, general & internal (96) 96
pharmacokinetics (94) 94
plant extracts - pharmacology (94) 94
sglt2 inhibitors (91) 91
apoptosis (90) 90
rats, sprague-dawley (90) 90
sodium-glucose transporter 2 - metabolism (90) 90
disease models, animal (89) 89
thiophenes - adverse effects (89) 89
hypoglycemia (88) 88
adolescent (87) 87
randomized controlled trials as topic (87) 87
type-2 diabetes-mellitus (87) 87
studies (86) 86
metformin - therapeutic use (85) 85
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1690) 1690
German (20) 20
Chinese (16) 16
Japanese (12) 12
Spanish (9) 9
French (4) 4
Danish (2) 2
Italian (2) 2
Portuguese (2) 2
Czech (1) 1
Dutch (1) 1
Hungarian (1) 1
Norwegian (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Diabetologia, ISSN 1432-0428, 2013, Volume 56, Issue 12, pp. 2582 - 2592
The aim of this work was to evaluate the efficacy and safety of canagliflozin vs placebo and sitagliptin in patients with type 2 diabetes who were being... 
Sodium glucose co-transporter 2 (SGLT2) inhibitor | Medicine & Public Health | Human Physiology | Canagliflozin | Metabolic Diseases | Internal Medicine | Sitagliptin | Metformin | Type 2 diabetes mellitus | GLIPIZIDE | ADD-ON | SULFONYLUREA | DAPAGLIFLOZIN | MELLITUS | INADEQUATE GLYCEMIC CONTROL | DIET | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | 52-WEEK | INHIBITOR | Blood Pressure | Triazoles - administration & dosage | Triazoles - adverse effects | Thiophenes - adverse effects | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Pyrazines - administration & dosage | Glycated Hemoglobin A - drug effects | Body Weight - drug effects | Lipids | Male | Thiophenes - administration & dosage | Metformin - adverse effects | Hypoglycemic Agents - administration & dosage | Aged, 80 and over | Female | Metformin - administration & dosage | Sitagliptin Phosphate | Drug Therapy, Combination | Glucosides - adverse effects | Fasting | Treatment Outcome | Blood Glucose - drug effects | Diabetes Mellitus, Type 2 - blood | Glucosides - administration & dosage | Adolescent | Pyrazines - adverse effects | Aged | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Complications and side effects | Care and treatment | Body weight | Glucose | Comparative analysis | Dextrose
Journal Article
The lancet. Diabetes & endocrinology, ISSN 2213-8587, 2015, Volume 3, Issue 1, pp. 8 - 10
Journal Article
Diabetes, obesity & metabolism, ISSN 1462-8902, 09/2017, Volume 19, Issue 9, pp. 1276 - 1288
.... Here, we examined these effects over 1 year in obese adults without diabetes. Materials and methods Obese adults without diabetes (N = 50; aged 18‐70 years... 
dapagliflozin | prediabetes | obesity | exenatide | ORLISTAT | SAFETY | RECEPTOR AGONISTS | RANDOMIZED-TRIAL | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | PLACEBO-CONTROLLED TRIAL | MANAGEMENT PROGRAMS | TYPE-2 | CARDIOVASCULAR RISK | ADVERSE EVENTS | Benzhydryl Compounds - administration & dosage | Follow-Up Studies | Obesity - drug therapy | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Male | Weight Loss - drug effects | Anti-Obesity Agents - therapeutic use | Peptides - administration & dosage | Hypoglycemic Agents - administration & dosage | Cardiovascular Diseases - epidemiology | Sodium-Glucose Transport Proteins - metabolism | Prediabetic State - etiology | Benzhydryl Compounds - therapeutic use | Glucosides - adverse effects | Body Mass Index | Hypoglycemic Agents - therapeutic use | Cardiovascular Diseases - etiology | Adiposity - drug effects | Anti-Obesity Agents - administration & dosage | Venoms - adverse effects | Risk Factors | Prediabetic State - prevention & control | Obesity - physiopathology | Membrane Transport Modulators - administration & dosage | Proof of Concept Study | Ghrelin - metabolism | Venoms - therapeutic use | Hypoglycemic Agents - adverse effects | Anti-Obesity Agents - adverse effects | Exenatide | Drug Therapy, Combination - adverse effects | Benzhydryl Compounds - adverse effects | Venoms - administration & dosage | Female | Glucosides - therapeutic use | Prediabetic State - epidemiology | Double-Blind Method | Drug Administration Schedule | Sweden - epidemiology | Ghrelin - agonists | Obesity - metabolism | Glucosides - administration & dosage | Membrane Transport Modulators - therapeutic use | Sodium-Glucose Transport Proteins - antagonists & inhibitors | Membrane Transport Modulators - adverse effects | Peptides - adverse effects | Peptides - therapeutic use | Original
Journal Article
International journal of clinical practice (Esher), ISSN 1368-5031, 2013, Volume 67, Issue 12, pp. 1267 - 1282
Summary Aims Canagliflozin is a sodium glucose co‐transporter 2 inhibitor developed for the treatment of type 2 diabetes mellitus (T2DM). This randomised,... 
BODY-WEIGHT | MEDICINE, GENERAL & INTERNAL | DIPEPTIDYL PEPTIDASE-4 INHIBITOR | GLYCEMIC CONTROL | PLACEBO | ADD-ON | DAPAGLIFLOZIN | DOUBLE-BLIND | 2 SGLT2 INHIBITOR | IMPROVES INDEXES | BETA-CELL FUNCTION | Thiophenes - adverse effects | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Male | Thiophenes - administration & dosage | Weight Loss - drug effects | Metformin - adverse effects | Dose-Response Relationship, Drug | Young Adult | Hypoglycemic Agents - administration & dosage | Aged, 80 and over | Adult | Female | Blood Pressure - drug effects | Sulfonylurea Compounds - administration & dosage | Metformin - administration & dosage | Glucosides - adverse effects | Insulin-Secreting Cells - physiology | Double-Blind Method | Drug Administration Schedule | Treatment Outcome | Sulfonylurea Compounds - adverse effects | Diabetes Mellitus, Type 2 - blood | Diabetes Mellitus, Type 2 - physiopathology | Canagliflozin | Glucosides - administration & dosage | Adolescent | Lipid Metabolism - drug effects | Aged | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Glucose metabolism | Care and treatment | Clinical trials | Hypoglycemic agents | Glucose | Cholesterol | Dextrose | Diabetes therapy | Patient safety | Pharmacology | Diabetes | Drug therapy | Clinical outcomes | Endocrinology
Journal Article
Diabetes (New York, N.Y.), ISSN 1939-327X, 2016, Volume 65, Issue 5, pp. 1190 - 1195
Pharmacologically induced glycosuria elicits adaptive responses in glucose homeostasis and hormone release. In type 2 diabetes (T2D), along with decrements in... 
INSULIN | SGLT2 | ENDOCRINOLOGY & METABOLISM | Glucose Intolerance - metabolism | Glycosuria - chemically induced | Carbohydrate Metabolism - drug effects | Lipolysis - drug effects | Benzhydryl Compounds - administration & dosage | Humans | Glucagon-Like Peptide 1 - blood | Diabetes Mellitus, Type 2 - metabolism | Insulin - blood | Glucagon - blood | Glucose Intolerance - blood | Glucose Intolerance - drug therapy | Benzhydryl Compounds - adverse effects | Hypoglycemic Agents - administration & dosage | Time Factors | Glucosides - therapeutic use | C-Reactive Protein - analysis | Benzhydryl Compounds - therapeutic use | Insulin Secretion | Glucosides - adverse effects | Hypoglycemic Agents - therapeutic use | 3-Hydroxybutyric Acid - blood | Sodium-Glucose Transporter 2 - metabolism | Glucose Intolerance - urine | 3-Hydroxybutyric Acid - agonists | Renal Elimination - drug effects | Sodium-Glucose Transporter 2 Inhibitors | Membrane Transport Modulators - administration & dosage | Diabetes Mellitus, Type 2 - urine | Diabetes Mellitus, Type 2 - blood | Insulin - metabolism | Algorithms | Glucosides - administration & dosage | 3-Hydroxybutyric Acid - metabolism | Lipid Metabolism - drug effects | Membrane Transport Modulators - therapeutic use | Glucagon - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Membrane Transport Modulators - adverse effects | Hypoglycemic Agents - adverse effects | Energy Metabolism - drug effects | Type 2 diabetes | Care and treatment | Glucagon | Dosage and administration | Triglycerides | Research | Insulin
Journal Article
Diabetes care, ISSN 1935-5548, 2015, Volume 38, Issue 3, pp. 420 - 428
Journal Article
Circulation (New York, N.Y.), ISSN 1524-4539, 2019, Volume 139, Issue 22, pp. 2528 - 2536
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2019, Volume 380, Issue 4, pp. 347 - 357
.... The primary safety outcome was a composite of major adverse cardiovascular events (MACE), defined as cardiovascular death, myocardial infarction, or ischemic stroke... 
MORTALITY | 2013 ACCF/AHA GUIDELINE | MEDICINE, GENERAL & INTERNAL | SELECTIVE SGLT2 INHIBITOR | MANAGEMENT | HEART-FAILURE OUTCOMES | DISEASE | AMERICAN-COLLEGE | ASSOCIATION TASK-FORCE | KIDNEY | EMPAGLIFLOZIN | Cardiovascular Diseases - etiology | Sodium-Glucose Transporter 2 Inhibitors - therapeutic use | Sodium-Glucose Transporter 2 Inhibitors - adverse effects | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Hospitalization - statistics & numerical data | Male | Benzhydryl Compounds - adverse effects | Cardiovascular Diseases - mortality | Female | Glucosides - therapeutic use | Aged | Diabetes Mellitus, Type 2 - drug therapy | Benzhydryl Compounds - therapeutic use | Heart Failure - epidemiology | Diabetes Mellitus, Type 2 - complications | Glucosides - adverse effects | Type 2 diabetes | Safety and security measures | Dapagliflozin | Dosage and administration | Drug therapy | Cardiovascular diseases | Risk factors | Heart failure | Myocardial infarction | Cerebral infarction | End-stage renal disease | Heart attacks | Mortality | Diabetes mellitus | Cardiovascular disease | FDA approval | Patients | Glomerular filtration rate | Heart rate | Ischemia | Sodium | Arteriosclerosis | Ketoacidosis | Death | Diabetes | Kidney diseases | Safety | Diabetes mellitus (non-insulin dependent) | Heart diseases | Life Sciences | Food and Nutrition | Animal biology | Cellular Biology | Pharmaceutical sciences | Cardiovascular Diseases | drug therapy | Benzhydryl Compounds | complications | Sodium-Glucose Transporter 2 Inhibitors | Hospitalization | prevention & control | Klinisk medicin | Diabetes Mellitus | etiology | Clinical Medicine | epidemiology | statistics & numerical data | adverse effects | mortality | Type 2 | Heart Failure | therapeutic use | Glucosides
Journal Article
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2016, Volume 375, Issue 4, pp. 323 - 334
Journal Article